Evidence map›Paper›PMID 41731210›Full record

ArticleHuman cell2026

Establishment and characterization of a novel sinonasal adenosquamous carcinoma cell line, TC717, with a high tumor mutational burden.

Ryosuke Kuga, Takeo Yamamoto, Takeshi Iwasaki, Midori Taniguchi, Tomomi Manako, Hidetaka Yamamoto, Yoshinao Oda

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryosuke KugaDepartment of Otorhinolaryngology-Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Takeo YamamotoDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Takeshi IwasakiDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Midori TaniguchiDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Tomomi ManakoDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Hidetaka YamamotoDepartment of Pathology, Graduate School of Medicine, Dentistry & Pharmaceutical Science, Okayama University, Okayama, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan. oda.yoshinao.389@m.kyushu-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We established and characterized a novel human sinonasal adenosquamous carcinoma (ASC) cell line, TC717, derived from a 64-year-old, never-smoking woman. The patient received neoadjuvant chemotherapy followed by total maxillectomy but succumbed to disease 6 months after therapy initiation. TC717 recapitulated the histologic and immunohistochemical hallmarks of ASC, including squamous differentiation (p40 positivity) and mucin production. The cells displayed a stable doubling time of ~ 27 h. WES revealed a high TMB in both the primary tumor tissue (43.0 mut/Mb) and the TC717 cell line (34.0 mut/Mb), and pathogenic TP53 c.614A > G and BRAF c.1574 T > C variants, neither previously reported in ASC. TC717 provides a valuable preclinical platform for investigating sinonasal ASC biology and for evaluating genotype-directed therapies.

Indexed as

Carcinoma, AdenosquamousMutationParanasal Sinus NeoplasmsCell Line, TumorFemaleHumansMiddle AgedProto-Oncogene Proteins B-rafTumor Suppressor Protein p53BRAF protein, humanProto-Oncogene Proteins B-rafTumor Suppressor Protein p53Adenosquamous carcinomaCell lineSinonasalTC717Tumor mutational burden

Identifiers

PMID41731210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.